Drug Discovery

Bionano frames $90M BioDiscovery buy as way to expand genomics analysis

Bionano Genomics is acquiring genomics software firm BioDiscovery in a $90 million cash and stock deal. While both companies provide genomics analysis solutions, Bionano said combining its technology with BioDiscovery’s software will provide the integrated offering that many labs want.

AI specialist Exscientia raises $510m in upsized IPO, placing

Exscientia’s artificial intelligence-based drug discovery engine is still largely unproven, but that hasn’t stopped the company raking in funding from investors keen to back its platform. The final numbers are now in from its recently announced initial public offering on the US Nasdaq, and the numbers are impressive, swelling from an initially forecast $304 million …

AI specialist Exscientia raises $510m in upsized IPO, placing Read More »

Open Source “Wikipedia” for Drug Discovery

By Kambiz Shekdar, Ph.D. Open source drug discovery was proposed in the past in connection with third-world diseases like tuberculosis and malaria, but it is in the context of first-world indications where it is needed most. Despite untold investment by numerous pharmaceutical companies, FDA-approved drugs that target critical brain functions and conditions like anxiety, depression, …

Open Source “Wikipedia” for Drug Discovery Read More »

3rd Inflammasome Therapeutics Summit

Discover the Intricacies of Inflammasome Regulation, Leverage Inflammasome Proteins as Biomarkers & Accelerate Novel Inflammasome Therapeutics into Proof-Of-Concept Clinical Trials & Beyond Built with Ventus Therapeutics, Inflammasome Therapeutics, Merck & more, the Inflammasome Therapeutics Summit returns for its third year as the only industry-dedicated forum to discover the intricacies of inflammasome regulation and accelerate novel …

3rd Inflammasome Therapeutics Summit Read More »

Lundbeck taps Inscopix’ brain-mapping camera tech for CNS research

Danish drugmaker Lundbeck has teamed up with Inscopix – the developer of a technology that can film neurons in the brain in real time – to try to find new drugs for central nervous system diseases. The two partners will use the nVista wearable microscope technology to develop a map of the brain and brain …

Lundbeck taps Inscopix’ brain-mapping camera tech for CNS research Read More »

A biotech startup’s hunt for elusive disease targets scores $60M for drug R&D

Atavistik Bio is one of several companies discovering and developing drugs that work by allostery, binding to less obvious sites of a target protein. Acting CEO John Josey said the startup aims to stand apart with its focus on understanding metabolic interactions, a path less trodden by others in allosteric drug discovery.

UPMC Launches Drug Discovery Company Novasenta to Develop Targeted Immunotherapy Drugs for Cancer

Mani Mohindru, Ph.D.,Chief Executive Officer, Novasent What You Should Know: – UPMC today announced the launch of Novasenta, a drug discovery and development company seeking novel and effective treatments for cancer.  Co-founded in late 2018 by Robert Ferris, M.D., Ph.D., Dario Vignali, Ph.D., and Greg Delgoffe, Ph.D., all of the UPMC Hillman Cancer Center and Pitt, Novasenta …

UPMC Launches Drug Discovery Company Novasenta to Develop Targeted Immunotherapy Drugs for Cancer Read More »

BMS buys into AI-designed immune drug from Exscientia

Bristol Myers Squibb has exercised an option on an immune-modulating drug candidate developed by UK artificial intelligence specialist Exscientia, paying $20 million for the buy-in as part of their $1.2 billion alliance. The unnamed drug candidate acts on an immunological kinase enzyme, which has proven hard to target using conventional drug discovery techniques because challenges …

BMS buys into AI-designed immune drug from Exscientia Read More »

AI firm XtalPi swells its coffers with another $400m financing

Artificial intelligence (AI) specialist XtalPi has chalked up a second big financing in the space of a year, raising $400 million and taking its valuation to around $2 billion. Founded several years ago by a team of MIT researchers and previously backed by Google, XtalPi deploys AI to a range of drug discovery and development …

AI firm XtalPi swells its coffers with another $400m financing Read More »

Bayer bolsters R&D platform with $2bn Vividion takeover

Bayer headlined its second-quarter results this morning by unveiling a deal to buy Vividion Therapeutics, saying it will boost its ability to develop medicines against targets once considered “undruggable.” Bayer is paying $1.5 billion upfront to claim ownership of Vividion‘s drug discovery platform, which uses chemoproteomics to identify new binding sites on proteins and find …

Bayer bolsters R&D platform with $2bn Vividion takeover Read More »

Google’s DeepMind puts human proteome online for free

The most complete database of protein structures ever assembled, developed with the help of Google’s artificial intelligence unit DeepMind, has been made freely available to researchers around the world. DeepMind partnered with the European Molecular Biology Laboratory (EMBL) to come up with the AlphaFold database, which predicts the three-dimensional structures of the human proteome – …

Google’s DeepMind puts human proteome online for free Read More »

Gates Foundation backs COVID R&D at AI firm Exscientia

Artificial intelligence-based drug discovery company Exscientia is stepping up its search for new COVID-19 medicines, thanks to an award by the Bill & Melinda Gates Foundation.  The $1.5 million grant will be used to develop a new class of small-molecule inhibitors of Mpro , a protease enzyme essential for the replication of the SARS-CoV-2 virus. …

Gates Foundation backs COVID R&D at AI firm Exscientia Read More »

4 Notable Life Sciences Trends from the Tech Trends Report

The Future Today Institute has released its 2021 Tech Trends Report (14th Annual Edition), a comprehensive report on strategic trends that it anticipates will affect business, government, education, media and society in the coming year. We noted four trends discussed in the report’s Health, Medicine & Science section that will be of particular interest to …

4 Notable Life Sciences Trends from the Tech Trends Report Read More »

BMS embraces AI drug discovery with $1.2bn Exscientia alliance

Exscientia has signed up another big pharma partner for its artificial intelligence (AI) based drug discovery platform, this time attracting a $50 million upfront buy-in from Bristol-Myers Squibb.  BMS wants to harness Exscientia’s tech to discover small-molecule drugs across a range of therapeutic categories – including immunology and oncology – and is promising another $125 …

BMS embraces AI drug discovery with $1.2bn Exscientia alliance Read More »

Exscientia starts trials of AI-designed Alzheimer’s drug

Exscientia has advanced a drug candidate for Alzheimer’s disease into human testing, the third clinical-stage project for the UK specialist in artificial intelligence (AI) based drug discovery.  The new molecule – called DSP-0038 – is being developed by Japan’s Sumitomo Dainippon Pharma (DSP), which is now starting a phase 1 trial in the US as …

Exscientia starts trials of AI-designed Alzheimer’s drug Read More »

Roivant’s move to go public reveals just how much its drug strategy has changed

Founded by former hedge fund manager Vivek Ramawamy, Roivant Sciences set out to redefine drug development by acquiring overlooked drugs and advancing their development. The merger deal that will take it public reveals how much new technology changed the company’s vision and its strategy.

InveniAI Collaborates with Shionogi on AI-Based Drug Discovery

Shots: InveniAI is eligible to receive up to $200M/ program as up front, development, and commercial milestones along with royalties The collaboration integrates InveniAI’s AI platform AlphaMeld to identify, evaluate, optimize novel targets with Shionogi’s expertise in developing and commercializing therapeutic modalities Shionogi will synthesize targets identified by InveniAI for certain strategic diseases and will …

InveniAI Collaborates with Shionogi on AI-Based Drug Discovery Read More »

Relay Therapeutics pays $85M for startup with a new AI tech for drug discovery

Relay Therapeutics has its own technology that applies artificial intelligence and machine learning techniques to drug discovery. Its $85 million acquisition of ZebiAI gives it another technology that applies ML to DNA-encoded libraries and predicts the small molecules with the potential to drug proteins.

Q1 2021 Health IT/Digital Health PC/VE, M&A, IPOs/ SPACs Activity

The first quarter of 2021 has been one of investor optimism as the vaccine rollout continues ahead of expectations and economic activity begins to accelerate in response.  Within the Health IT industry, the already strong investment and M&A trends seen in 2020 have only accelerated.  Over the course of the quarter, we observed $7 billion in private …

Q1 2021 Health IT/Digital Health PC/VE, M&A, IPOs/ SPACs Activity Read More »

Exscientia starts trials of first AI-derived cancer immunotherapy

Exscientia was the first company to start human trials of a new drug designed using artificial intelligence (AI) last year, and now says it has started testing of the first AI candidate for immuno-oncology.  Oxford, UK-based Exscientia has been working with German biotech Evotec on the adenosine A2a receptor antagonist, which is being tested as …

Exscientia starts trials of first AI-derived cancer immunotherapy Read More »

AI drug discovery player 1910 Genetics debuts with $26m war chest

There’s a new kid on the block among companies using artificial intelligence in drug discovery, after 1910 Genetics launched today with $26 million in financing. The Cambridge, Massachusetts-based startup claims it is the only biotech launched so far that will use AI to design both small-molecule drugs and protein therapeutics, coupled with automated biological testing …

AI drug discovery player 1910 Genetics debuts with $26m war chest Read More »

Takeda Collaborates with Evotec on RNA Targeting Drug Development

Shots: Evotec to receive research funding and will be eligible for $160M/program as discovery, pre/ clinical, a commercial milestone along with royalties on sales of product emerges from the collaboration The collaboration will utilize Evotec’s RNA targeting platform to identify RNA sequences to target with small-molecule ligands aligned that can be developed into the first-in-class …

Takeda Collaborates with Evotec on RNA Targeting Drug Development Read More »

Welsh startup Antiverse raises $2m for antibody discovery toolkit

New biotech Antiverse has raised seed funding of £1.4 million ($2 million) to develop its artificial intelligence-based platform for discovering therapeutic antibodies. The Cardiff, Wales startup is combining machine learning and phage display techniques to model antibody-antigen binding and says it can cut the time it takes to develop a drug candidate. It’s one of …

Welsh startup Antiverse raises $2m for antibody discovery toolkit Read More »

AI drug discovery firm Valence joins Parkinson’s disease push

Canada’s Valence Discovery has joined a University of Montreal-led project to try to find new drugs to treat the involuntary movement complications that can accompany treatments for Parkinson’s disease.  The go-to treatment for the five million people worldwide with Parkinson’s is levodopa, which replaces the activity of the dopamine neurotransmitter dopamine that gets depleted by …

AI drug discovery firm Valence joins Parkinson’s disease push Read More »

Exscientia Secures $100M To Expand AI Drug Discovery Platform

What You Should Know: – Exscientia, leading AI drug discovery company, today announced that it completed its $100 million Series C financing round, with a further $30 million investment from Blackrock. – This new capital, which will be used to support Exscientia’s platform development and proprietary pipeline, follows Exscientia’s demonstrated high growth, having announced earlier this year …

Exscientia Secures $100M To Expand AI Drug Discovery Platform Read More »

Roivant extends AI drug discovery reach with $450M Silicon Therapeutics buyout

Roivant Sciences is expanding its drug discovery and design capabilities via a stock deal to acquire Silicon Therapeutics. The Boston startup uses physics-based modeling to simulate proteins and the small molecules that bind to them.

UCB Collaborates with Microsoft to Accelerate Drug Discovery and Development

Shots: The collaboration will merge Microsoft’s computational services, cloud and AI with UCB’s drug discovery and development capabilities The companies intend to discover and develop medicines for people living with severe diseases in immunology and neurology. The collaboration follows UCB and Microsoft’s collaboration around COVID-19 Microsoft will provide AI technology and applied scientists to work …

UCB Collaborates with Microsoft to Accelerate Drug Discovery and Development Read More »

Microsoft, UCB Launch Collaboration to Accelerate Drug Discovery and Development

What You Should Know: – Global biopharma company UCB and Microsoft announced today a new, multi-year strategic collaboration to advance UCB’s digital transformation, change the way care is delivered, and accelerate better outcomes for people living with severe diseases. – The partnership builds on the companies’ joint work as part of the COVID Moonshot project which sought to create …

Microsoft, UCB Launch Collaboration to Accelerate Drug Discovery and Development Read More »

Alzheimer’s Research UK starts AI-based drug hunt with Exscientia

Medical charity Alzheimer’s Research UK has teamed up with artificial intelligence specialist Exscientia to find new drug treatments for the devastating neurodegenerative disease.  The alliance will see Exscientia work with the charity’s Oxford Drug Discovery Institute (ODDI) to find therapeutics that target the neuroinflammation associated with Alzheimer’s disease (AD), focusing in particular on the NLRP3 …

Alzheimer’s Research UK starts AI-based drug hunt with Exscientia Read More »

Evotec Collaborates with Related Sciences for Drug Discovery and Development

Shots: Evotec to receive milestones, royalties, and a founding equity stake in all Related Sciences assets developed under the collaboration Evotec and Related Sciences will jointly discover & develop a multitude of therapeutic approaches with IND filings over a multi-year period. The partnership will combine Related Sciences’ collaborative model and data-driven approach to identify biological …

Evotec Collaborates with Related Sciences for Drug Discovery and Development Read More »

Artificial Intelligence in Drug Discovery – Could help Reduce Significant Capital and Time Required

Drug discovery is a complex process which involves significant utilization of time and resources. As per several sources, on an average, the entire drug development process (from initial proof-of-concept to commercial launch) takes around 10-15 years and capital investments worth USD 4-10 billion to develop a drug from concept to commercial launch. The early stages …

Artificial Intelligence in Drug Discovery – Could help Reduce Significant Capital and Time Required Read More »

Advancing Healthcare Delivery via Artificial Intelligence

Artificial Intelligence have demonstrated intelligent behavior through their ability to learn, communicate with its users and solve complex problems using highly sophisticated algorithms. AI-driven technologies have continued to evolve rapidly, with several industries increasingly deploying such solutions across key aspects of value chain. Furthermore, AI is also made with same idea of making tasks simpler …

Advancing Healthcare Delivery via Artificial Intelligence Read More »

Roche Collaborate with Cambridge Quantum Computing to Develop Quantum Algorithm for Drug Discovery and Development

Shots: CQC collaborates with Roche to design and implement noisy-intermediate-scale-quantum (NISQ) algorithms for early-stage drug discovery and development The collaboration will employ CQC’s quantum chemistry platform ‘EUMEN’, to augment the Roche’s AD research efforts The multi-year collaboration will combine the expertise of both CQC and Roche to advance the application of quantum computing to pharmaceutical …

Roche Collaborate with Cambridge Quantum Computing to Develop Quantum Algorithm for Drug Discovery and Development Read More »

Elsevier to Work with Heel for Mechanism-based Drug Action Discovery

Elsevier, the data analytics business specialized in science and health, and Heel, a pharmaceutical company specialized in developing and manufacturing medicines made from natural ingredients, have recently completed a series of research projects with a focus on improving exploratory preclinical studies. “We at Heel are pioneers in the field of systems research and have a …

Elsevier to Work with Heel for Mechanism-based Drug Action Discovery Read More »

30 Executives Share Top Healthcare Predictions & Trends to Watch in 2021

As we close out the year, we asked several healthcare executives to share their predictions and trends for 2021. Kimberly Powell, Vice President & General Manager, NVIDIA Healthcare Federated Learning: The clinical community will increase their use of federated learning approaches to build robust AI models across various institutions, geographies, patient demographics, and medical scanners. The sensitivity and …

30 Executives Share Top Healthcare Predictions & Trends to Watch in 2021 Read More »

AI drug discovery biotech AbCellera eyes record IPO

AbCellera Biologics has been in the spotlight since coming up with Eli Lilly’s COVID-19 antibody drug bamlanivimab, and looks set to capitalise on that exposure with a sizeable initial public offering. The Vancouver, Canada-headquartered biotech – which has been bankrolled in part by billionaire entrepreneur and venture capitalist Peter Thiel – plans to offer 23 …

AI drug discovery biotech AbCellera eyes record IPO Read More »

How the rare disease community has developed fertile ground for progress

Amanda Barrell explores how a perfect storm of changing economics, advances in technology, and the increasing volume of the patient voice is stoking change in the rare disease space. New models of drug development are fuelling life-changing advantages in the rare disease space, previously an economic no-go area for pharma and biotech companies. That was …

How the rare disease community has developed fertile ground for progress Read More »

BioNTech, InstaDeep plan joint lab for AI research

BioNTech may be deeply ensconced in the latter stages of its bid to bring a COVID-19 vaccine to market, but it’s still pushing forward on other fronts, including a partnership with InstaDeep to deploy artificial intelligence and machine learning across its business. The two companies have been working together in this area since 2019, but …

BioNTech, InstaDeep plan joint lab for AI research Read More »

Johnson & Johnson Innovation Launches 3 Collaborations to Advance Healthcare in China

Front row (left to right): Jian Chen, Vice President, Xian Janssen Pharmaceuticals; Dan Wang, Head, Johnson & Johnson Innovation, Asia Pacific; Sharona Tao, Leader, Communications & Public Affairs, Johnson & Johnson China; Jennifer Yang, Head, Lung Cancer Initiative China, Johnson & Johnson Back row (left to right): Alex Zhavoronkov, Founder & CEO, Insilico Medicine; Li …

Johnson & Johnson Innovation Launches 3 Collaborations to Advance Healthcare in China Read More »

Mission Bio Launches Single-Cell Multi-Omics System for Precision Cancer Therapies

What You Should Know: – Mission Bio launches industry’s first and only single-cell multi-omics platform, is announcing the launch of its most comprehensive instrument to-date, to save the industry billions of dollars in drug development costs and bring life-saving treatments to market at least six months faster. – Mission Bio’s Tapestri Platform, the first single-cell …

Mission Bio Launches Single-Cell Multi-Omics System for Precision Cancer Therapies Read More »

BMS joins forces with insitro to develop neurodegenerative treatments

insitro has landed another big biopharma partnership, signing a five-year collaboration with Bristol Myers Sqibb to develop therapies for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).  Neurodegenerative disorders such as ALS and FTD are considered a challenging therapeutic area, with no disease modifying treatments available today. insitro uses machine-learning technology to discover novel drug …

BMS joins forces with insitro to develop neurodegenerative treatments Read More »

JPC Taps Proscia to Modernize World’s Largest Human Tissue Repository

What You Should Know: – The U.S. government’s Joint Pathology Center, which houses the world’s largest human tissue repository, today announced that Proscia, a leading digital and AI pathology company, will provide end-to-end modernization of JPC’s pathology operations. – The multi-phase project will digitize the world’s largest human pathology specimen repository in order to enhance …

JPC Taps Proscia to Modernize World’s Largest Human Tissue Repository Read More »

REAL-WORLD EVIDENCE: THE GAME CHANGER IN DRUG DEVELOPMENT

While the definition of real world evidence is still evolving, most proponents associate it with data that is derived from medical practice among heterogeneous sets of patients in the real world setting. It is the integration of data gathered from various sources, such as EHRs, medical charts, patient claims and billing activities, product and disease …

REAL-WORLD EVIDENCE: THE GAME CHANGER IN DRUG DEVELOPMENT Read More »

Roche Collaborates with Genesis Therapeutics for AI-Driven Drug Discovery

Shots: Genesis to receive an up front and is eligible to receive pre/ clinical and regulatory milestones along with royalties on sales of approved drugs emerges from the collaboration The collaboration leverages Genesis’ graph machine learning and drug discovery expertise to identify drug candidates for therapeutic targets across multiple disease areas Genesis has developed Dynamic …

Roche Collaborates with Genesis Therapeutics for AI-Driven Drug Discovery Read More »

How DNA-encoded Libraries Boost Drug Discovery

DNA-encoded libraries (DELs) have been gaining a lot of traction in hit finding and drug discovery in recent years. Regarded by some as a truly revolutionary advance in chemistry, a DEL is a mixture of millions of small molecules in which each molecule is conjugated to a DNA-oligomer that encodes its chemical structure. The mixture …

How DNA-encoded Libraries Boost Drug Discovery Read More »

4 Areas Driving AI Adoption in Hospital Operations and Patient Safety

Renee Yao, Global Healthcare AI Startups Lead at NVIDIA COVID-19 has put a tremendous burden on hospitals, and the clinicians, nurses, and medical staff who make them run.  Many hospitals have suffered financially as they did not anticipate the severity of the disease. The extended duration of patient stays in ICUs, the need for more …

4 Areas Driving AI Adoption in Hospital Operations and Patient Safety Read More »

Scripps Research, Repurpose.AI Partner to Develop COVID-19 Therapeutics

What You Should Know: – Repurpose.AI, has partnered with Scripps Research to discover drug candidates that may be repurposed to treat COVID-19.  – The partnership will leverage Repurpose.AI’s ActivPred AI Drug Discovery Platform, an unbiased drug, target, and disease agnostic digital chemistry engine, to discover drug candidates to treat COVID-19.  Scripps Research is teaming up …

Scripps Research, Repurpose.AI Partner to Develop COVID-19 Therapeutics Read More »

Increasing Rate of Drug Failure has Prompted the Drug Developers to Rely on CROs offering In Vitro ADME Testing Services for their Outsourcing Requirements

It is important to note that the process of drug discovery is extremely demanding, both in terms of capital and time. In fact, the overall amount spent on R&D initiatives in the pharmaceutical / biotechnology sector has increased from around USD 128 billion in 2008 to USD 165 billion in 2018. Moreover, only a small …

Increasing Rate of Drug Failure has Prompted the Drug Developers to Rely on CROs offering In Vitro ADME Testing Services for their Outsourcing Requirements Read More »

Rising Popularity of Drug Targeting Synthetically Lethal Targets Fuels the Battle of PARP Inhibitors for Treatment of Advanced Cancer Indications

Cancer is considered to be the second leading cause of mortality, after cardiovascular diseases, accounting for every sixth reported death in the world. The International Agency for Research on Cancer (IARC) states that the number of new cancer cases is expected to grow to 27.5 million across the globe, by 2040. Experimental evidence has shown …

Rising Popularity of Drug Targeting Synthetically Lethal Targets Fuels the Battle of PARP Inhibitors for Treatment of Advanced Cancer Indications Read More »

Targeted Protein Degradation – Defining a New Frontier in the Field of Medicine

The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. While conventional medicines, such as small molecule inhibitors and monoclonal antibodies, address fewer than 20% of the proteome, targeted protein degradation offers a unique means to tap into the rest of the …

Targeted Protein Degradation – Defining a New Frontier in the Field of Medicine Read More »

In Silico / Computer-Aided Drug Discovery Service Providers for Large Molecules

Over time, the complexities associated with drug discovery have increased, especially in case of large molecule drugs, which are inherently more complex than conventional small molecules. As a result, an increase in the overall research and development (R&D) expenditure in the pharmaceutical / biotechnology sector has been witnessed. In addition to the complexities involved, the …

In Silico / Computer-Aided Drug Discovery Service Providers for Large Molecules Read More »